Want to see SE:MNTC full AI Analyst Report?
Top Page
Mentice AB
(MNTC)
Select Model
Select Model
Rating:60Neutral
Price Target:
kr15.50
▲(15.67% Upside)
Action:Reiterated
Date:07/24/26
The score is driven mainly by improving financial performance (revenue and cash flow recovery with low leverage) but is held back by continued losses and negative ROE. Technical indicators add support with clear price strength versus key moving averages and a positive MACD, while valuation remains a meaningful drag due to the negative P/E and lack of dividend yield data.
Positive Factors
Niche simulation product offering
Mentice’s specialized VR/haptics simulation platform and procedure content target a high-value niche: image-guided endovascular training. This specialization creates durable product differentiation, strong B2B relationships with hospitals and device makers, and recurring content/license demand.
Negative Factors
Ongoing losses / negative ROE
Despite improvements, persistent negative EBIT/net income and below-zero ROE limit internal capital generation and the company’s ability to self-fund growth. Continued losses constrain strategic optionality, slow return on invested capital, and require either sustained margin improvement or external financing to reach durable profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Niche simulation product offering
Mentice’s specialized VR/haptics simulation platform and procedure content target a high-value niche: image-guided endovascular training. This specialization creates durable product differentiation, strong B2B relationships with hospitals and device makers, and recurring content/license demand.
Read all positive factors
Mentice AB (MNTC) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr420.48M
Dividend YieldN/A
Average Volume (3M)19.32K
Price to Earnings (P/E)―
Beta (1Y)0.79
Revenue Growth15.87%
EPS Growth92.43%
CountrySE
Employees119
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.17
Shares Outstanding28,125,734
10 Day Avg. Volume26,429
30 Day Avg. Volume19,315
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)2.71
Price to Sales (P/S)1.34
P/FCF Ratio-14.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.16
Revenue Forecast (FY)kr318.25M
Mentice AB Business Overview & Revenue Model
Company Description
Mentice AB (publ), founded in 1998 and headquartered in Gothenburg, Sweden, specializes in delivering advanced endovascular simulation solutions. These are utilized by educational institutions, healthcare systems, and medical device manufacturers ...
How the Company Makes Money
Mentice makes money primarily by selling and licensing simulation-based training solutions used for interventional procedure education. Key revenue streams include: (1) System sales and solutions delivery: revenue from providing simulator systems ...
Mentice AB Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
72
Positive
Cash Flow
48
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 303.13M | 279.09M | 290.33M | 273.61M | 217.95M | 185.06M |
| Gross Profit | 128.19M | -33.06M | 257.25M | 236.38M | 188.94M | 149.92M |
| EBITDA | 18.86M | -1.72M | 18.30M | 28.87M | 266.00K | 1.44M |
| Net Income | -4.61M | -32.33M | -18.42M | -2.82M | -30.66M | -29.19M |
Balance Sheet | ||||||
| Total Assets | 298.51M | 312.02M | 323.90M | 322.53M | 332.98M | 261.90M |
| Cash, Cash Equivalents and Short-Term Investments | 61.07M | 33.38M | 53.59M | 59.12M | 47.28M | 12.70M |
| Total Debt | 13.56M | 16.82M | 9.14M | 9.56M | 16.68M | 14.70M |
| Total Liabilities | 174.93M | 173.65M | 180.24M | 163.55M | 170.34M | 125.02M |
| Stockholders Equity | 123.58M | 138.38M | 143.66M | 158.97M | 162.63M | 136.89M |
Cash Flow | ||||||
| Free Cash Flow | 18.40M | -25.43M | 1.48M | 29.53M | 1.85M | -31.03M |
| Operating Cash Flow | 25.41M | -20.30M | 17.92M | 36.52M | 14.91M | -5.13M |
| Investing Cash Flow | -12.65M | -15.46M | -16.44M | -16.18M | -32.28M | -25.90M |
| Financing Cash Flow | 21.79M | 19.66M | -9.31M | -7.05M | 48.99M | -5.78M |
Mentice AB Technical Analysis
Positive
13.40
Price Trends
13.63
Positive
13.59
Positive
13.36
Positive
Market Momentum
0.33
Negative
55.84
Neutral
50.15
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:MNTC, the sentiment is Positive. The current price of 13.4 is below the 20-day moving average (MA) of 14.12, below the 50-day MA of 13.63, and above the 200-day MA of 13.36, indicating a bullish trend. The MACD of 0.33 indicates Negative momentum. The RSI at 55.84 is Neutral, neither overbought nor oversold. The STOCH value of 50.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:MNTC.
Mentice AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | kr1.24B | 24.84 | 14.08% | 0.26% | -0.27% | 93.40% | |
60 Neutral | kr420.48M | -87.27 | -3.61% | ― | 15.87% | 92.43% | |
52 Neutral | kr583.48M | -69.38 | -2.84% | ― | -13.72% | 52.47% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | kr283.08M | -6.70 | -106.02% | ― | 26.25% | 43.03% | |
45 Neutral | kr295.37M | -5.44 | -25.09% | ― | -14.57% | 16.16% | |
43 Neutral | kr98.38M | -1.40 | -66.41% | ― | -47.42% | 44.01% |
* Healthcare Sector Average
SE:MNTC
Mentice AB
14.55
-1.20
-7.62%
SE:CLS.B
Clinical Laserthermia Systems AB Class B
1.83
-3.99
-68.54%
SE:BACTI.B
Bactiguard Holding AB
15.80
-13.10
-45.33%
SE:CRAD.B
C-Rad AB Class B
35.60
1.70
5.03%
SE:ACARIX
Acarix AB
0.25
-0.13
-35.26%
SE:BRAIN
BrainCool AB
0.76
-0.72
-48.61%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.